Analysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN) and Akili (AKLI)
TD Cowen Sticks to Its Buy Rating for Akili (AKLI)
LifeSci Capital Reaffirms Their Buy Rating on Akili (AKLI)
Credit Suisse Reiterates Outperform on Akili, Maintains $4 Price Target
Akili Analyst Ratings
Akili (AKLI) Receives a Buy From LifeSci Capital
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bausch Health Companies (BHC), PTC Therapeutics (PTCT) and Akili (AKLI)
LifeSci Capital Reaffirms Their Buy Rating on Akili (AKLI)
Akili (AKLI) Gets a Buy From LifeSci Capital
LifeSci Capital Reaffirms Their Buy Rating on Akili (AKLI)
Morgan Stanley Sticks to Its Hold Rating for Akili (AKLI)
Morgan Stanley Adjusts Price Target on Akili to $3 From $2, Maintains Equal-Weight Rating
Akili Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Akili, Raises Price Target to $3
LifeSci Capital Reaffirms Their Buy Rating on Akili (AKLI)
Update: Morgan Stanley Initiates Akili at Equalweight, $2 Price Target, Cites Uncertainties Regarding EndeavorRx's Launch
Akili Analyst Ratings
Morgan Stanley Initiates Coverage On Akili With Equal-Weight Rating, Announces Price Target of $2
Akili Analyst Ratings
B of A Securities Initiates Coverage On Akili With Neutral Rating, Announces Price Target of $2